Brian Brohman

Twitter LinkedIn

Prior to joining NX Prenatal, Mr. Brohman held the position of Chief Financial Officer and/or Chief Business Officer at oncology drug development firms Bradmer Pharmaceuticals Inc. [TSX: BMR] and Aptamera, Inc. (private company). As a co-founder of Bradmer, Mr. Brohman guided all aspects of the company’s business operations from its inception in 2005 through 2009. Activities included the licensing of Bradmer’s technology from Duke University, the raising over $35 million in equity financing, and the negotiation of all major vendor contracts and clinical study agreements with leading cancer centers across the US.

While at Aptamera, Mr. Brohman led that company’s fundraising and licensing activities beginning in February 2002 through its successful sale in February 2005 to London-based Antisoma plc. Prior to Aptamera, Mr. Brohman served in a variety of corporate finance and business development roles during an 8-year tenure with Cordis Corp., a multi-billion dollar medical device division of Johnson & Johnson.

A graduate of the University of Notre Dame with a BBA in Finance, Mr. Brohman has over 20 years experience in corporate finance and business development, including 16 years in the medical technology field. Since 1995, Mr. Brohman has specialized in the field of business development, and is a veteran of over 100 mergers, acquisitions, licensing and equity financing deals.